Day: December 11, 2019

CHICAGO, Dec. 11, 2019 (GLOBE NEWSWIRE) — The Board of Directors of Oil-Dri Corporation of America (NYSE: ODC) today declared quarterly cash dividends of $0.25 per share of the Company’s Common Stock and $0.1875 per share of the Company’s Class B Stock.The dividends declared will be payable on February 28, 2020 to stockholders of record at the close of business on February 14, 2020. The Company has paid cash dividends continuously since 1974 and has increased dividends annually for sixteen consecutive years.While Oil-Dri’s founding product was granular clay floor absorbents, it has since greatly diversified its portfolio. The Company’s mission to “Create Value from Sorbent Minerals” is supported by its wide array of consumer and business to business product offerings. In 2016, Oil-Dri celebrated its seventy-fifth year of business...

LITTLE ROCK, Ark., Dec. 11, 2019 (GLOBE NEWSWIRE) — Bank OZK (Nasdaq: OZK) (the “Bank”) announced plans for a significant investment for the construction of a solar power plant which will provide enough renewable energy to power its new corporate headquarters and up to 40 other Arkansas locations, according to Tim Hicks, Chief Administrative Officer and Executive Director of Investor Relations. The Bank’s investment of over $6 million represents the largest investment in renewable energy by an Arkansas-based financial services company to date. The solar power plant, expected to be located in Central Arkansas, will be the third-largest commercial solar facility dedicated to a private sector customer in the State of Arkansas, and will have generating capacity of 4.8-megawatts DC of electricity.“Bank OZK is pleased to be at the forefront...

LIVERMORE, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) — FormFactor, Inc. (Nasdaq: FORM) today updated its prior outlook for Revenue, Gross Margins and Earnings Per share for its fiscal fourth quarter of 2019 ending December 28, 2019.FormFactor now expects the following outlook*:              *This outlook assumes consistent foreign currency rates.**Reconciling items are amortization of intangibles, stock-based compensation, restructuring charges, and acquisition related expenses.Mike Slessor, CEO of FormFactor, Inc., said, “The incremental demand driving our increased outlook ranges reflects the same factors that contributed to our previously disclosed, sequentially-stronger fourth quarter outlook: Strength in Foundry and Logic, overlaid on continued robust demand in our other businesses. This incremental demand is more significant...

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as the company’s president and chief operating officer. In this new role, Dr. Suliman will oversee Alector’s day-to-day operations, including preclinical development, program management, and strategic and administrative functions. Dr. Suliman will report to Arnon Rosenthal, Ph.D., chief executive officer of Alector.“Shehnaaz’s background and expertise in drug development, strategy, portfolio management, and operational leadership uniquely position her to bring greater integration to our operations. Her strong track record of building and leading teams that can support the development of life-changing...

— Comparable Sales Increased 6% —— GAAP and Adjusted EPS of $0.10 at Top of Guidance Ranges —— Narrows Full-Year GAAP EPS Guidance Range to $4.15 – $4.30 and Full-Year Adjusted EPS to $4.25 – $4.40 —ATLANTA, Dec. 11, 2019 (GLOBE NEWSWIRE) — Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its fiscal 2019 third quarter ended November 2, 2019. Consolidated net sales in the third quarter of fiscal 2019 grew to $241.2 million compared to $233.7 million in the third quarter of fiscal 2018. Earnings on a GAAP basis were $0.10 per share in the third quarter of fiscal 2019 compared to earnings of $0.11 per share in the same period of the prior year. On an adjusted basis, earnings were $0.10 per share in the third quarter of fiscal 2019 compared to earnings of $0.14 per...

NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European Patent Office (“EPO”) issued European Patent No. 2968992 to the Company on December 11, 2019. This patent, “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Mannitol,” includes 14 claims directed to compositions comprising eutectics of cyclobenzaprine hydrochloride and mannitol and methods of making those compositions.  This patent is expected to provide Tonix with market exclusivity until 2034.Seth Lederman, M.D., President and Chief Executive Officer of Tonix commented, “The issuance of this European patent is an important step forward in our efforts to broaden our intellectual property estate on a global basis for...

TORONTO, Dec. 11, 2019 (GLOBE NEWSWIRE) — Colliers International Group Inc. (NASDAQ: CIGI) (TSX: CIGI) (“Colliers“) announced today that its board of directors has declared a semi-annual cash dividend on the outstanding Subordinate Voting Shares and Multiple Voting Shares (together, the “Common Shares“) of Colliers of US$0.05 per Common Share. This dividend is in accordance with the dividend policy of Colliers. The dividend is payable on January 14, 2020 to holders of Common Shares of record at the close of business on December 31, 2019. The dividend is an “eligible dividend” for Canadian income tax purposes.About Colliers InternationalColliers International (NASDAQ, TSX: CIGI) is a leading global real estate services and investment management company. With operations in 68 countries, our 14,000...

Expecting topline data in Q3 2020 from truncated Phase 2 SOLAR clinical trial of cobomarsen in CTCLPursuing guidance from FDA on a clinical development plan for cobomarsen in ATLL; anticipate meeting in Q2 2020Focusing future pipeline efforts primarily on the development of MRG-229 for the treatment of IPF; preclinical data expected in Q2 2020Announces interim data from a Phase 2 clinical trial of remlarsen in keloid scarsAnnounces additional reduction in work force as part of strategic shift and cost realignmentAnnounces the departure of Paul Rubin, M.D., Executive Vice President of R&D and transition plan promoting Diana Escolar, M.D. to the position of Chief Medical OfficerExtends anticipated cash runway into Q4 2020Entered into a $20 million firm commitment common stock purchase agreement with Aspire Capital Fund, LLC, including...